Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL.

J Neurochem. 2007 May;101(3):749-56.

2.

Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.

Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA.

ACS Chem Neurosci. 2017 Jun 21;8(6):1170-1176. doi: 10.1021/acschemneuro.7b00063. Epub 2017 Mar 10.

PMID:
28263550
3.

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.

Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA.

PLoS One. 2013 Aug 23;8(8):e71634. doi: 10.1371/journal.pone.0071634. eCollection 2013.

4.

Immunological features of alpha-synuclein in Parkinson's disease.

Roodveldt C, Christodoulou J, Dobson CM.

J Cell Mol Med. 2008 Oct;12(5B):1820-9. doi: 10.1111/j.1582-4934.2008.00450.x. Epub 2008 Jul 30. Review. Erratum in: J Cell Mol Med. 2008 Dec;12(6B):2875.

5.

Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation.

Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV, Morozova-Roche LA, Sewell RD.

Neuroimmunomodulation. 2012;19(6):334-42. doi: 10.1159/000341400. Epub 2012 Sep 11.

6.

Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.

Brudek T, Winge K, Folke J, Christensen S, Fog K, Pakkenberg B, Pedersen LØ.

Mol Neurodegener. 2017 Jun 7;12(1):44. doi: 10.1186/s13024-017-0187-7.

7.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
8.

α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.

Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA.

PLoS One. 2011 Apr 25;6(4):e18513. doi: 10.1371/journal.pone.0018513.

9.

Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.

Heinzel S, Gold M, Deuschle C, Bernhard F, Maetzler W, Berg D, Dodel R.

PLoS One. 2014 Dec 3;9(12):e114566. doi: 10.1371/journal.pone.0114566. eCollection 2014.

10.

Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.

Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Fernandez-Montesinos R, Caro M, Lachaud CC, Waudby CA, Delgado M, Dobson CM, Pozo D.

PLoS One. 2010 Oct 26;5(10):e13481. doi: 10.1371/journal.pone.0013481.

11.

L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.

Schmitt I, Kaut O, Khazneh H, deBoni L, Ahmad A, Berg D, Klein C, Fröhlich H, Wüllner U.

Mov Disord. 2015 Nov;30(13):1794-801. doi: 10.1002/mds.26319. Epub 2015 Jul 14.

PMID:
26173746
12.

Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.

Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, Poewe W, Reindl M, Oertel WH, Noelker C, Bacher M, Dodel R.

Neurology. 2013 Jan 8;80(2):169-75. doi: 10.1212/WNL.0b013e31827b90d1. Epub 2012 Dec 19.

PMID:
23255825
13.

α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.

Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A.

Hum Mol Genet. 2012 Jul 15;21(14):3173-92. doi: 10.1093/hmg/dds143. Epub 2012 Apr 18.

PMID:
22513881
14.

CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes.

Schiess MC, Barnes JL, Ellmore TM, Poindexter BJ, Dinh K, Bick RJ.

BMC Neurosci. 2010 Nov 29;11:151. doi: 10.1186/1471-2202-11-151.

15.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P.

Mov Disord. 2014 Jul;29(8):1019-27. doi: 10.1002/mds.25772. Epub 2014 Jan 16.

16.

α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls.

Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA.

PLoS One. 2012;7(12):e52285. doi: 10.1371/journal.pone.0052285. Epub 2012 Dec 17.

17.

Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.

Chiba-Falek O, Lopez GJ, Nussbaum RL.

Mov Disord. 2006 Oct;21(10):1703-8.

PMID:
16795004
18.

Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.

Garcia-Esparcia P, Hernández-Ortega K, Koneti A, Gil L, Delgado-Morales R, Castaño E, Carmona M, Ferrer I.

Acta Neuropathol Commun. 2015 Dec 1;3:76. doi: 10.1186/s40478-015-0257-4.

19.

Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.

Pchelina S, Emelyanov A, Baydakova G, Andoskin P, Senkevich K, Nikolaev M, Miliukhina I, Yakimovskii A, Timofeeva A, Fedotova E, Abramycheva N, Usenko T, Kulabukhova D, Lavrinova A, Kopytova A, Garaeva L, Nuzhnyi E, Illarioshkin S, Zakharova E.

Neurosci Lett. 2017 Jan 1;636:70-76. doi: 10.1016/j.neulet.2016.10.039. Epub 2016 Oct 22.

PMID:
27780739
20.

Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.

Lawand NB, Saadé NE, El-Agnaf OM, Safieh-Garabedian B.

Expert Opin Ther Targets. 2015;19(10):1351-60. doi: 10.1517/14728222.2015.1062877. Epub 2015 Jul 1. Review.

PMID:
26135549

Supplemental Content

Support Center